<DOC>
	<DOCNO>NCT01937260</DOCNO>
	<brief_summary>This phase 1 , multi-center , open-label , drug-drug interaction ( DDI ) PK study subject moderate severe plaque psoriasis . It design evaluate effect brodalumab midazolam PK addition assess single dose PK brodalumab subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Brodalumab Drug-Drug Interaction ( DDI ) Intensive Pharmacodynamic ( PK ) Study Psoriasis Subjects</brief_title>
	<detailed_description>Approximately 30 subject enrol two group . Group 1 consist 20 subject receive 2 oral dos midazolam single subcutaneous ( SC ) dose brodalumab . Group 2 consist 10 subject receive single SC dose brodalumab .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month body mass index ( BMI ) ≥ 18.0 ≤ 38.0 kg/m2 body weight ≥ 50 ≤ 130 kg know history active tuberculosis Female subject lactating/breastfeeding History evidence clinically significant disorder , condition disease , opinion investigator Amgen physician would pose risk subject safety interfere study evaluation , procedures completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>